REVO News 0.0060 06/09/2014 05:24:04 Revolutionary Conc (REV

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Revolutionary Conc (REVO) 0.0060 $REVO

Revolutionary Concepts Announces Its Global Licensee Partner Hires Top Law Firm to Negotiate Sublicensing Deals to Other Companies to Generate Royalties
Marketwire - Thu Jun 05, 2:09AM CDT
Revolutionary Concepts Inc., (OTC Pink: REVO) (PINKSHEETS: REVO), a publicly traded company that develops online mobile video software and remote security communication systems, announced that its global Licensee partner has engaged one of the top law firms in the country to assist in the negotiations to sublicense REVO's patented EyeTalk Communicator System to other companies. The law firm is one of the largest in the country that specializes in negotiating patent agreements, collaboration deals and intellectual property to sublicense to other companies.

Revolutionary Concepts Announces First Quarter 2014 Financial and Operating Results and Reports a Net Income of $774,106
Marketwire - Fri May 30, 12:55PM CDT
Revolutionary Concepts Inc., (OTCQB: REVO), a publicly traded company that develops mobile video software and remote security communication systems, announced that it has filed its Quarterly Report on Form 10-Q for its first quarter ended March 31, 2014 with the Securities and Exchange Commission. The Report contains the Company's financial statements, management's discussion and analysis (MD&A), its plans and future outlook and other disclosures. The Results of Operations was excerpted from the Form 10-Q Report.

Revolutionary Concepts Inc. Advances Negotiations With Developer in Three Billion Dollar Toy Market With Focus on Smart Toy and Cloud Based Interaction
Marketwire - Wed Mar 26, 1:15PM CDT
Revolutionary Concepts Inc. (OTCQB: REVO), a publicly traded company that develops mobile video software and remote security communication systems, has begun advanced contract negotiations to further the process of bringing its Smart Toy technology to market via patent sale and/or licensing agreements.

Revolutionary Concepts Inc. Forecasts up to $30 Million in Annual Revenue
ACCESSWIRE - Fri Mar 21, 8:40AM CDT
Revolutionary Concepts Inc. (OTCQB: REVO), a security technology and monitoring company in the developmental stage, saw its volume soar Mar. 20, with 14,797,383 shares changing hands.

Revolutionary Concepts Forecasts $30 Million in Revenues, Announces Major Plans to Increase Investor Returns and Shareholder Value
Marketwire - Wed Mar 19, 11:25AM CDT
Revolutionary Concepts Inc., (OTCQB: REVO), a publicly traded company that develops mobile video software and remote security communication systems, plans major new initiatives to significantly increase investor returns and improve shareholder value. After REVO announced it signed a multi-year global licensing agreement with its Licensee to commercialize REVO's patented "EyeTalk Communicator System", REVO is forecasting $20 to $30 million in total estimated annual revenues from residual licensing fees and royalties.

Revolutionary Concepts Stock Rises 873%, Breaks Trading Barriers, Trades 79.26 Million Shares
Marketwire - Wed Feb 19, 2:00PM CST
Revolutionary Concepts Inc., (OTCQB: REVO), a publicly traded company that develops online mobile video software and remote security communication systems, announced that shares of its common stock rose in price more than 842%, in the past two weeks. Based on today's intraday trading, its price has traded as high as $0.0185, as compared to its previous low closing price set on Monday, February 3, 2014. On Tuesday, February 18, 2014, the Company's stock traded over 70.26 million shares

Revolutionary Concepts Announces Major Plans to Maximize Revenues From Its Global License Agreement of Its Online Smart Technology Security System
Marketwire - Tue Feb 18, 10:40AM CST
Revolutionary Concepts Inc. (OTCQB: REVO), a publicly traded company that develops online mobile video software and remote security communication systems, announced it is working in conjunction with the Licensee that it signed a global multi-year licensing agreement to aggressively commercialize REVO's patented "EyeTalk Communicator System." Both companies are reviewing various options and alternatives to fully exploit and maximize the potential financial revenues and profits that could be obtained from the patents and license agreement.

Revolutionary Concepts Stock Soars 182%, on News of Global License Deal, Forecasts $30 Million in Sales, and Sets New Trading Record of 120 Million Shares Sold
Marketwire - Thu Feb 13, 9:55AM CST
Revolutionary Concepts Inc., (OTCQB: REVO), a publicly traded company that develops online mobile video software and remote security communication systems, announced that shares of its common stock broke all previous trading records and soared more than 182%. A record 120,588,619 shares of its stock traded on Wednesday, February 12, 2014, after REVO reported that it signed a multi-year global licensing agreement with a company for them to commercialize REVO's patented "EyeTalk Communicator System."

Revolutionary Concepts, Inc. Reveals Additional Information on Potential Sale of Patent Portfolio
ACCESSWIRE - Wed Sep 18, 1:25PM CDT
CHARLOTTE, NC September 18, 2013 - (ACCESSWIRE) - Revolutionary Concepts, Inc., a company focused on the design and development of intellectual property (IP) rights, and trade names such as Eye Talk Communicator (OTCQB: REVO) (http://www.revolutionaryconceptsinc.com/) could receive an immediate benefit of several hundred thousand dollars from the sale and/or license of patents, discussed in our previous press release.

Revolutionary Concepts, Inc. Seeks Board Approval to Close Sale of Multi-Million Dollar Patent Portfolio
Marketwire - Thu Sep 12, 1:13PM CDT
Revolutionary Concepts, Inc., a company focused on the design and development of intellectual property (IP) rights, and trade names such as Eye Talk Communicator (OTCQB: REVO) (www.revolutionaryconceptsinc.com) seeks Director approval for shareholder vote to finalize the sale and/or license of patents.

Revolutionary Concepts, Inc. Estimates Revenues Generate From Licensing Fees
GlobeNewswire - Fri Sep 06, 9:00AM CDT
Revolutionary Concepts, Inc. (OTCBB:REVO) (www.revolutionaryconceptsinc.com), a company focused on the design and development of intellectual property (IP) rights, and trade names such as Eye Talk Communicator discussed the marketability of the patent portfolio and estimations of licensing fees.

Revolutionary Concepts, Inc. Signs Letter of Intent for Patent Rights
GlobeNewswire - Tue Sep 03, 2:15PM CDT
Revolutionary Concepts, Inc. is a company focused on the design and development of intellectual property (IP) rights, and trade names such as Eye Talk Communicator. Revolutionary Concepts, Inc. (OTCBB:REVO) (www.revolutionaryconceptsinc.com) announced today that it has executed a Letter of Intent with an undisclosed third party to acquire the rights to patents US 7,193,644 B2; US 8,139,089 B2; US 8,144,183 B2; US 8,144,184 B2; US 8,154,581 B2; US 8,164,614 B2 as well as negotiate licensing agreements.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 655

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 406

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 83

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 18

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

VivoPower Innovates with XRP-Focused Treasury Strategy

Updated Category News Views 359

VivoPower's Transformational XRP Strategy VivoPower International PLC (NASDAQ: VVPR) has recently embarked on a groundbreaking journey by announcing a new strategy centered on the digital asset XRP. The company is positioning itself as the first publicly traded entity to implement an XRP-focused digital asset treasury. This innovative approach is not only exciting for...

Continue Reading
Recognizing Excellence in Product Stewardship for 2024

Updated Category News Views 114

Celebrating Product Stewardship Excellence The Product Stewardship Society has announced a significant honor for 2024—Lynn L. Bergeson has been named the recipient of the prestigious Allan K. Fleeger Distinguished Service Award. This esteemed award has been established to acknowledge the remarkable contributions of individual product stewards who have played crucial...

Continue Reading
Gold Hits New Heights Amid Tensions and Election Uncertainty

Updated Category News Views 163

Gold Prices Surge to Record Heights In recent trading, gold prices have reached unprecedented levels, reflecting a significant rise driven by various factors, including political uncertainties and ongoing international conflicts. As anticipation surrounding a highly competitive U.S. presidential election grows, along with persistent tensions in regions such as the Middle...

Continue Reading
Paul Jebely Joins Sterlington as Aviation Law Vice Chair

Updated Category News Views 257

Paul Jebely Joins Sterlington as New Partner Sterlington PLLC is excited to announce that Paul Jebely has joined the firm as their new Partner and Vice Chair of International, marking a crucial advancement in their aviation law practice. Jebely is not just any attorney; he is a globally recognized authority in private aviation law, especially known for his work with...

Continue Reading
William James Wartinbee III Executes Significant Sell Strategy

Updated Category News Views 62

William James Wartinbee III Implements Key Sell Strategy In a noteworthy insider sale, William James Wartinbee III, the Executive Vice President at Gartner (IT), has sold 210 shares of the company. This transaction was documented in a Form 4 filing with the U.S. Securities and Exchange Commission, and the sale was valued at about $103,275. Examining Gartner's Current...

Continue Reading